Department of Microbiology & Immunology, Center for Molecular and Tumor Virology, Feist-Weiller Cancer Center, Louisiana State University Health Sciences Center-Shreveport, Shreveport, LA, USA.
Center for Cardiovascular Diseases and Sciences, Louisiana State University Health Sciences Center-Shreveport, Shreveport, LA, USA.
Methods Mol Biol. 2021;2244:1-18. doi: 10.1007/978-1-0716-1111-1_1.
Human cytomegalovirus (HCMV) is a betaherpesvirus with a global seroprevalence of 60-90%. HCMV is the leading cause of congenital infections and poses a great health risk to immunocompromised individuals. Although HCMV infection is typically asymptomatic in the immunocompetent population, infection can result in mononucleosis and has also been associated with the development of certain cancers, as well as chronic inflammatory diseases such as various cardiovascular diseases. In immunocompromised patients, including AIDS patients, transplant recipients, and developing fetuses, HCMV infection is associated with increased rates of morbidity and mortality. Currently there is no vaccine for HCMV and there is a need for new pharmacological treatments. Ongoing research seeks to further define the complex aspects of HCMV pathogenesis, which could potentially lead to the generation of new therapeutics to mitigate the disease states associated with HCMV infection. The following chapter reviews the advancements in our understanding of HCMV pathogenesis in the immunocompetent and immunocompromised hosts.
人巨细胞病毒(HCMV)是一种β疱疹病毒,其全球血清流行率为 60-90%。HCMV 是先天性感染的主要原因,对免疫功能低下的个体构成巨大健康风险。尽管 HCMV 感染在免疫功能正常的人群中通常无症状,但感染可导致单核细胞增多症,并且还与某些癌症以及各种心血管疾病等慢性炎症性疾病的发展有关。在免疫功能低下的患者中,包括艾滋病患者、移植受者和发育中的胎儿,HCMV 感染与发病率和死亡率的增加有关。目前尚无针对 HCMV 的疫苗,需要新的药物治疗方法。正在进行的研究旨在进一步明确 HCMV 发病机制的复杂方面,这可能会导致产生新的治疗方法来减轻与 HCMV 感染相关的疾病状态。以下章节综述了我们在免疫功能正常和免疫功能低下宿主中对 HCMV 发病机制的理解方面的进展。